TY - JOUR
T1 - Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors
AU - Torrisi, Rosalba
AU - Dellapasqua, Silvia
AU - Ghisini, Raffaella
AU - Viale, Giuseppe
AU - Veronesi, Paolo
AU - Luini, Alberto
AU - Intra, Mattia
AU - Peruzzotti, Giulia
AU - Rocca, Andrea
AU - Balduzzi, Alessandra
AU - Cardillo, Anna
AU - Goldhirsch, Aron
AU - Colleoni, Marco
PY - 2008/12
Y1 - 2008/12
N2 - Preoperative chemotherapy and endocrine therapy yielded low pathological complete remission (pCR) rates in patients with endocrine responsive breast cancer. Patients with large operable (cT2-T3, N0-2, M0), ER ≥10% breast cancer were treated in two consecutive studies with preoperative chemotherapy (Study I: six courses of either fluorouracil, leucovorin, vinorelbine (FLN), or vinorelbine, cisplatin, and continuous infusion of fluorouracil (ViFuP), at the discretion of the treating physician; Study II: capecitabine and oral vinorelbine (CAVINO)). Concurrent letrozole (in association with triptorelin if premenopause) was given. Sixty-five (58 evaluable) and 55 (all evaluable) patients were enrolled in the two studies. In Study I there were 43 objective responders (74%, 95% CI 63-85%), three of whom had pCR. Thirty-nine objective responses (91%) and all pCR were observed in patients with tumors expressing ER ≥50%. In Study II 34 patients (62%, 95% CI 49-75%) had an objective response. Endocrine therapy administered together with new intravenous, containing regimens should be explored in the preoperative treatment of endocrine responsive breast cancer.
AB - Preoperative chemotherapy and endocrine therapy yielded low pathological complete remission (pCR) rates in patients with endocrine responsive breast cancer. Patients with large operable (cT2-T3, N0-2, M0), ER ≥10% breast cancer were treated in two consecutive studies with preoperative chemotherapy (Study I: six courses of either fluorouracil, leucovorin, vinorelbine (FLN), or vinorelbine, cisplatin, and continuous infusion of fluorouracil (ViFuP), at the discretion of the treating physician; Study II: capecitabine and oral vinorelbine (CAVINO)). Concurrent letrozole (in association with triptorelin if premenopause) was given. Sixty-five (58 evaluable) and 55 (all evaluable) patients were enrolled in the two studies. In Study I there were 43 objective responders (74%, 95% CI 63-85%), three of whom had pCR. Thirty-nine objective responses (91%) and all pCR were observed in patients with tumors expressing ER ≥50%. In Study II 34 patients (62%, 95% CI 49-75%) had an objective response. Endocrine therapy administered together with new intravenous, containing regimens should be explored in the preoperative treatment of endocrine responsive breast cancer.
KW - Breast cancer
KW - Chemoendocrine therapy
KW - Predictive factors
KW - Primary therapy
UR - http://www.scopus.com/inward/record.url?scp=56649102283&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=56649102283&partnerID=8YFLogxK
U2 - 10.1016/j.breast.2008.05.002
DO - 10.1016/j.breast.2008.05.002
M3 - Article
C2 - 18595702
AN - SCOPUS:56649102283
VL - 17
SP - 654
EP - 660
JO - Breast
JF - Breast
SN - 0960-9776
IS - 6
ER -